Fayetteville | 479-755-4510
Bentonville | 479-777-0657
Schedule Now

Innovations

Our Innovative Technology

Think about how much more enjoyable your daily activities will be with enriched vision. At Vold Vision, better vision is achieved every day for the people who have chosen to trust their eyes to us. Vold Vision provides the most advanced medical, laser, and surgical care available for treating a wide variety of eye conditions and diseases. As part of Vold Vision's commitment to providing the best care and treatment for their patients, we are pleased to offer advanced treatments like Xen, and iStent. Dr. Vold has worked on the XEN, and iStent, all of which are FDA-approved and ordered fairly often for his surgeries. Patients travel from all across the United States and the world to get cutting edge treatments like these that restore their vision and improve their life at Vold Vision in Northwest Arkansas.

XEN

Dr. Vold was the first U.S. surgeon to place the XEN 45 Gel Stent in the initial FDA trial, and he is the first surgeon in the state of Arkansas to perform the surgery after the XEN received FDA approval in November 2016. A soft, permanent, subconjunctival implant that shunts fluid from the anterior chamber to the subconjunctival space, the XEN is yet another tool for ophthalmologist when caring for complex glaucoma cases. Patients are seeing a much-improved recovery experience and regaining control of their intraocular pressures.

iStent

iStent is the smallest medical device ever approved by the FDA. It is placed in your eye during cataract surgery and is so small that you won’t be able to see or feel it after the procedure is over. iStent is designed to create a permanent opening in your trabecular meshwork, and works continuously to improve the outflow of fluid from your eyes to help control eye pressure. If Dr. Vold determines you are a candidate for the iStent and it is implanted during your cataract surgery, it will begin to manage your eye pressure immediately. And with the iStent implanted, you may experience a reduction in glaucoma medications.